Marketresearchnews

Thursday, 27 September 2018

Neuropathology Market- Global Industry Size, Share, Trends, Analysis and Forecast 2018 – 2023

Market Synopsis of the Global Neuropathology Market

Neuropathology pertains to the aliment of nerves reculting in pain and numbness of the limbs and it is gaining prominence in this market. The increasing incidence of musculoskeletal conditions and technological advancements in medical diagnostic devices are some factors responsible for the growth of the global neuropathology market.

The number of patients suffering from cerebrovascular disorders has increased rapidly and has reached an all-time high in the past few years. There has been a significant rise in the number of surgeries associated with the treatment of such disorders. As the neurosurgeries and spinal surgeries are very critical, continuous monitoring during the whole procedure proves to be beneficial as the information about the electrical signals in brain and the nerves can be obtained in real time.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4978

Biopsies primarily consist of the skin. The recently developed neuropathy test, the epidermal nerve fiber density testing (ENFD) in which the nerve fibers of the skin is analysed by performing a punch skin biopsy to identify small fiber neuropathies. This pathology test is becoming available in selected labs as well as a few universities; it replaces the traditional sural nerve biopsy test and is less invasive. It is used to identify painful small fiber neuropathies.

According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases. Many healthcare professionals have started using these diagnostics techniques, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for Neuropathology.

The Global market of Neuropathology is expected to grow at a CAGR of approximately 6% during the forecast period 2017-2023.

Key Players

Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.

ARUP Laboratories
Therapath LLC
Abbott Laboratories
Laboratory Corporation of America Holdings
Thermo Fisher Scientific Inc.
Hoffmann-La Roche Ltd.
Sakura Finetek USA Inc.
Danaher Corporation
Quest Diagnostics Incorporated
Agilent Technologies Inc.N
NeoGenomics Laboratories

Segmentation

The Neuropathology is segmented on the basis of diagnosis test, application, and end-users.

On the basis of diagnostic test, the market is segmented into the biopsy, body fluids, peripheral blood smears, tissue resections, and others

The biopsy sub-segment is divided into Epidermal nerve fiber density testing (ENFD), Sural nerve biopsy test, bone-marrow biopsies, lymph-node biopsies and others

On the basis of product, the application market is segmented into cerebral hypoxia and stroke, perinatal disorders, CNS infections, demyelinative diseases, brain tumors, neurodegenerative diseases, inherited metabolic disorders, peripheral neuropathy, and myopathology

On the basis of end-user, the market is segmented into hospitals, clinics, research centers and others.

Regional Analysis

The Global Neuropathology Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.

North America dominated the global neuropathology market owing to the increasing healthcare expenditure in North America since 2016. U.S. has some of the best hospitals in the world with state of the art infrastructure. Most of the hospitals and their neurology departments are well equipped with the equipment that is required for the working of the neuropathology techniques. Various organizations and private companies are engaged in the activities of spreading awareness about the benefits of the neuropathology test among common people through various educational and marketing ways. As a result, huge numbers of people are opting for the neuropathology tests as a point of care. The country has been developing number of academic courses to develop skilled personnel in the neuropathology field over the years. Hence the availability of the neuropathology specialists in North American countries is high.

Europe is the second largest market for neuropathology market. For Europe, the neuropathology market including the brain tumors market is regarded as a strong competitive market. European countries are now making efforts in promoting the benefits of the intraoperative neurophysiological monitoring services. Patient friendly healthcare and insurance policies are making a positive impact on the people taking medical assistance.

Asia Pacific is the fastest growing region over the forecast period. The healthcare spending in Asia increased due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.

Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/4978

Table Of Content

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/4978

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Wednesday, 26 September 2018

Global Pericardium Diseases Market Trends, Demand and Forecast to 2023

Market Scenario:

The pericardium is a double-layered, tough, collagenous membrane, which surrounds the heart. They play an important role in the protection of the health from external shock. Nowadays, a number of companies manufacture artificial tissue membrane, which is widely used in the surgical procedures of pelvic floor reconstruction and bariatric stomach reduction. Many factors are responsible for the diseases, which includes infections, heart surgery, trauma, cancer and many other diseases. Pericarditis is the most common type of the disease. It affects people of all ages, however, men between 20 years-50 years are more likely to develop the disease. In 15%-30% cases, it develops into chronic pericarditis. Increasing prevalence of pericarditis across the globe is a major driver of the market. According to the Health Grades Inc, 1 in every 2,000 individual have pericarditis. Additionally, high healthcare expenditure, increasing demand for the better treatment, and rising number of patients with heart diseases are providing support for the growth of the market. However, available treatments are costly and are not affordable to peoples in developing countries. Thus, the high cost of the treatment may slow the growth of the market.

The globalpericardium diseases market is expected to grow at a CAGR of ~8.2 % during the forecast period 2017-2023.

Intended Audience

Pharmaceutical Companies
Government and private research companies
Research and Development (R&D) Companies
Drug Manufacturers and Suppliers
Medical Research Laboratories

SegmentationThe global pericardium diseases market is segmented on the basis of types, treatment, and end users.

On the basis of the types, the market is segmented into acute pericarditis, hemopericardium, pericarditis, tuberculous pericarditis, and others.

On the basis of the treatment, the market is segmented into diagnostic test, and disease treatment. The diagnostic treatment is further segmented into the physical exam, EKG, chest X-ray, echocardiography, cardiac CT, cardiac MRI, and others. The diseases treatment is sub-segmented into anti-inflammatory drugs, pericardium patches, surgery, and others.

On the basis of the end users, the market is segmented into hospital & clinics, ambulatory centers, and others.

Regional AnalysisThe Americas account for the major share of the global pericardium diseases market owing to the increasing number of patients with pericardium diseases, well-developed technology, and increasing government support for research & development. Additionally, high healthcare expenditure and changing lifestyle have fuelled the growth of the Americas pericardium diseases market. Presence of major players in this region is likely to support the growth of the market during the forecasted period.Europe holds the second largest pericardium diseases market, which is followed by Asia Pacific. Strong government support and availability of the funds for research & development have driven the market growth. Germany and the U.K are the major contributors to the market. Asia Pacific is the fastest growing pericardium diseases market owing to the presence rapidly developing the economy, increasing the prevalence of cancer and other heart diseases, and increasing government support.
On the other hand, the Middle East & Africa hold the least share of the market due to poor political conditions in Africa, and limited availability of funds and medical facilities. The Middle East dominates the Middle East & Africa pericardium disease market due to the presence of well-developed countries like Kuwait, Qatar, Oman, and South Arabia. However, due to the presence of a huge opportunity for the development of the market, Africa region is expecting a healthy growth.

Key Players in Global Pericardium Market

Some of key the players in the market are Smith and Nephew (U.K), Teva Pharmaceutical (Isreal), GlaxoSmithKline Plc. (U.K), Novartis AG (Switzerland), Eli Lilly and Company (U.S.), Arthrex, Inc.(U.S.), Medtronic (U.K), Edwards Lifesciences (U.S.), Abbott Laboratories (U.S.), Johnson & Johnson Services, Inc. (U.S.), C.R. Bard Inc (U.S.)Allergan (U.S.), Integra Lifesciences (U.S.), Livanova(U.K), and Zimmer Biomet (U.S.)

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4897

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Folliculitis Market Competitive landscape By 2023

Market synopsis of global folliculitis market:

Market Scenario:

Folliculitis is very common health problems across the globe. About 3 million cases found per year in the US alone. Folliculitis can be noninfectious or infectious. Although, most of the cases of folliculitis are infectious. Increasing knowledge of folliculitis, rapid adoption of products, and increasing healthcare expenditure are driving this market. Emerging economies account for a major share of the global folliculitis market which is expected to grow at the CAGR of ~4.7% during the forecast period and is estimated to reach USD 561.3 million by 2023.

Study objectives of global folliculitis market:

To provide detailed analysis of the global folliculitis market structure with historical and forecast revenue for the next six years of the various segments and sub-segments.
To provide insights about the key drivers, restraints, opportunities and challenges affecting the growth of global folliculitis market
To provide analysis of the market with respect to various countries in the four main geographies– the Americas, Europe, Asia-Pacific, and Middle East & Africa.
To provide detailed analysis of the market segmented by type, treatment, end user, and its sub-segments.
To provide a detailed analysis of global folliculitis market mainly based on Value Chain analysis, Porter’s Five Forces, Price analysis, and Supply Chain analysis etc.
To provide a detailed country level analysis of the market with respect to the current market size and future prospects.
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global folliculitis market.
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the folliculitis market.

Segments:
Global folliculitis market has been segmented on the basis of type which comprise superficial folliculitis, deep folliculitis, and others. Superficial folliculitis is sub-segmented into bacterial folliculitis, hot tub folliculitis (pseudomonas folliculitis), barber's itch (pseudofolliculitis barbae), pityrosporum folliculitis. Deep folliculitis is sub-segmented into sycosis barbae, gram-negative folliculitis, boils (furuncles) and carbuncles, eosinophilic folliculitis.
On the basis of treatments, the market has been segmented into medication, warm compress, medicated shampoo, and others. Medication is sub-segmented into antibiotics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), antifungals, antivirals, and others.
On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes, and others.
Regional analysis of global folliculitis market:
Considering the global scenario of the market, the Americas is holding largest market share. Some major factors are driving the growth in America such as large amount of money invested in R&D, and clinical trials. European market is second largest and countries like Germany and UK are holding largest market share. Increasing healthcare spending is major factor for Asia Pacific folliculitis market. While due to lack of knowledge of the disease and limited access to the healthcare facilities, Middle East and Africa is growing slower than the global average.
Key players for global folliculitis market:

Some of the key players in this market are: AbbVie Inc. (US), Allergan (Republic of Ireland), AstraZeneca (UK), CELGENE CORPORATION (US), GlaxoSmithKline plc. (UK), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Pfizer Inc.(US), and others.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/3823

Influenza Diagnostics Market 2018 World Analysis and Forecast to 2023

Market Synopsis of Global Influenza Diagnostics Market:

Market Scenario:

Global Influenza Diagnostics Market is growing moderately. Influenza or flu is one of the common medical condition which occur in seasonal epidemics and shows an acute illness with variable degrees of systemic symptoms which ranges from mild fatigue to respiratory failure and death. Influenza B is most common type of flu. Influenza infection can create health complications which may be deadly, but early diagnosis of influenza can reduces the chances of further complications. According the World Health organization, there are almost 600 million cases of influenza worldwide. The increasing demand for advanced diagnostic products and kits, increasing R&D funding for new innovative products and increasing healthcare expenditure are major driving factors for this market. The Global Influenza Diagnostics market is expected to reach US$ 700.7 million by 2023 and is projected to grow at the CAGR of ~5.8% during the forecast period from 2017-2023.

Study objectives of Global Influenza Diagnostics Market:

To provide detailed analysis of the Global Influenza Diagnostics market structure with historical and forecasted revenue for the next 6 years of the various segments and sub-segments of the influenza diagnostics Market
To provide insights about the key drivers, restraints, opportunities and challenges that affecting the growth of the Influenza Diagnostics market
To provide analysis of the market with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
To provide detail analysis of the market that segmented on the basis of type of flue, test type, by end user, and its sub-segments.
To provide detail analysis of global Influenza Diagnostics market mainly based on Value chain analysis, Porter’s five forces, Price analysis, and Supply Chain analysis etc.
To provide detail country level analysis of the market with respect to the current market size and future prospective
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Influenza Diagnostics Market
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

Key Players for Global Influenza Diagnostics Market:
Some of the key players in this market are: Alere (US), BD (US), Becton, Dickinson and Company (U.S.), Cepheid (US), bioMérieux SA (France), Hardy Diagnostics(us), LifeSign LLC.(US), Meridian Bioscience, Inc.(US), Quidel Corporation (US), Roche Molecular Systems Inc.(Switzerland), Sekisui Diagnostics (US)

Segments:

Global Influenza Diagnostics Market has been segmented on the basis of type of flu which comprise Type A flu (Seasonal flu, Swine Flu, Bird Flu), type B flu, Type C flu. On the basis of type of test it segmented into Molecular Tests, Rapid Influenza Detection Tests (RIDT), Direct Fluorescent Antibody (DFA) Tests, Nucleic Acid Sequence-based Amplification (NASBA) Tests, Serological Assays, Simple Amplification-based Assays (SAMBA), Loop-mediated Isothermal Amplification-based Assays (LAMP), and Others. Serological assays further sub segmented into Primary Serological tests (Enzyme linked immunosorbent assay (ELISA), Immuno fluorescent antibody technique (IFAT), Radio immuno assay (RIA), Secondary Serological tests (Agglutination tests, Complement fixation tests (CFT), Precipitation tests, Serum neutralization tests (SNT), Toxin-antitoxin test), and Tertiary serological tests.

Regional Analysis of Global Influenza Diagnostics Market:

Considering the global scenario of the market, North America is believed to be the largest market for Global Influenza Diagnostics due to advanced healthcare facilities and increasing presence of major players in this region. Moreover, the European market second largest market for Global Influenza Diagnostics. In Europe, Western Europe accounts the largest market share. While Asia-Pacific is expected to grow at significant rate in the Global Influenza Diagnostics market during the forecasted period. Middle East and Africa is likely to have a limited growth in the market due to less awareness of these therapies and treatment.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/3142

Acute Care EHR Market Global Segmentation and Major key Players Analysis 2023

Market ScenarioThe Electronic Health Record (EHR) is a longitudinal electronic record of patient health information including medication, past medical history, complications, patient demographics, progress notes, immunizations, vital signs, laboratory data and others. The acute care EHR differ slightly from the hospital and ambulatory EHR. The Acute Care EHR generates a patient information showing all clinical details, for operating room, emergency department, ICU, or any inpatient unit. During the last decade, there has been a significant increasing in the number of patients suffering from cancer, diabetes, heart disease, stroke among others which has increased the number of hospitals across the globe. According to the Center of Diseases Control and Prevention (2015), chronic diseases are responsible for 7 out of 10 deaths per year across the globe. The global acute care EHR is majorly driven by the increasing number of inpatients, rising prevalence of chronic diseases, and increasing number of hospitals & ambulatory centers. The increasing requirement of remote monitoring of geriatric patients has played a crucial role in creating demand for the improving healthcare facilities. Healthcare IT has helped in overcoming this problem and has improved the quality of treatment and also helped in the healthcare maintenance. Moreover, introduction of the advanced healthcare software and adoption of advanced devices & technology by healthcare has boosted the growth of the market. Due to the use of the advanced technology, the cost of the treatment is increased which is affecting the affordability of patients in the developing countries. High cost of the devices and treatment may slow the growth of the market. The globalacute care EHR market is expected to grow at a CAGR of ~7.0 % during the forecast period 2017-2023.

Key PlayersCerner Corporation (Siemens) (U.S.), Allscript (U.S.), Healthland (U.S.), Medhost (U.S.), McKesson Corporation (U.S.), Evident (CPSI) (U.S.), Epic Systems Corporation (U.S.), Meditech (U.S.), Athenahealth (RazorInsights) (U.S.), General Electric Company (U.S.), IBM (U.S.), Vitera Healthcare Solutions (U.S.), and eClinicalWorks (U.S.)

SegmentationsThe global acute care EHR market is segmented on the basis of deployment, application, and end users.
On the basis of deployment, the market is segmented into On-Premises based, Web-based.
On the basis of application, the market is segmented into personal care, pharmaceuticals, and others.

On the basis of end users, the market is segmented into hospital, ambulatory care and others.

Regional Analysis
The Americas dominate the global acute care EHR market owing to the increasing number of hospitals ambulatory centers, presence of huge patient population and well developed technology. The hospital and clinics are able to afford the cost of the devices as these are funded by several sources: the public sector, charities, health insurance companies, health organizations of all kinds, etc. Additionally, the people in this region are able to afford high cost of treatment on account of higher per capita income in this region. Rapidly increasing patient population, governments have started supporting the manufacturers for the development of new and better devices which has driven the growth of the market. Moreover, well developed technology, high healthcare expenditure, and huge geriatric population have fuelled the growth of the market in this region.

Europe commands the second largest market for acute care EHR which is followed by Asia Pacific. Availability of funds, strong government support, and increasing need for the better management devices & platform drive the growth of the market in Europe. Western Europe holds a major share of the market due to the presence of well developed economies. U.K, Germany and France are the major contributors of the market.

Asia Pacific is the fastest growing acute care EHR market owing to the increasing number of patients suffering from chronic diseases and rapidly increasing number of hospitals & clinics. Additionally, rapidly growing economies and increasing healthcare expenditure will fuel the growth of the market. On the other hand, the Middle East & Africa hold the least share of the market owing to less availability of funds, limited availability of medical facilities, and poor political conditions in Africa.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4930

Skin Biopsy Market- Global Industry Size, Share, Trends, Analysis and Forecast 2018 – 2023

Market Synopsis of the Global Skin Biopsy Market

Skin biopsy is a procedure involving the removal of skin for examination and providing information about any disease or clinical conditions. It is performed to determine the presence of any cancerous cells or any type of skin diseases. Skin cancer, actinic keratosis, dermatitis, psoriasis, and skin infection are various diseases that can be diagnosed through skin biopsy. During the procedure, the sample taken from the affected or diseased part of the skin is placed in formaldehyde solution, the tissue is processed and then examined under the microscope.

Rising of skin cancer and number of skin disease such as psoriasis, viral skin infection, and dermatitis, and growing demand for minimally invasive medical procedures are major factors contributing to the market growth. Furthermore, rising expenditure on the medical devices and instruments boost the market growth. However, high cost of treatment for skin diseases restrains the market.

The global skin biopsy market is expected to grow at a CAGR of 9.4% during the forecast period.

Key Players in the Global Skin Biopsy Market

Some of the key players in this market are Boston Scientific Corporation (U.S.), COOK Medical (U.S.), BD (U.S.), DTR Medical Ltd (U.K), Devicor Medical Products, Inc. part of Leica Biosystems. (U.S.), Gallini Srl (Italy), Hologic, Inc. (U.S.), and Cardinal Health (U.S.).

Segments

The global skin biopsy market is segmented on the basis of type, devices, indication, and end user.

On the basis of type, market is segmented into shave biopsy, punch biopsy, excisional biopsy and incisional biopsy.

On the basis of devices, the market is segmented into needle based biopsy guns, biopsy curettes and punches, guidance systems, biopsy forceps, biopsy needles and others.

On the basis of indication, the market is segmented into actinic keratosis, dermatitis, psoriasis, skin infection, cancer, and others.

Skin infection is further segmented into viral infections, deep fungal infections, basal cell carcinoma, squamous cell carcinoma, and melanoma.

On the basis of end user, the market is segmented into hospitals, dermatology clinics, and others.

Regional Analysis of the Global Skin Biopsy Market

America secures a leading position in the market for skin biopsy owing to the rising prevalence of skin diseases and cancer in the U.S. and presence of key market players. According to the American Academy of Dermatology (AAD), skin diseases affects one in every fourth American. The prevalence of skin diseases is also found to be increasing in Canada.

Europe is the second largest market for skin biopsy. Increasing prevalence of skin diseases such as fungal infections, and dermatitis, and increasing demand for technological advanced diagnostic services further drive the market growth.

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the rising geriatric population, rising prevalence of skin cancer, and increasing number of biopsies performed in the hospitals.

The Middle East & Africa also show a steady rise in the market owing to increasing prevalence of diabetes and other chronic diseases

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4650

Tuesday, 25 September 2018

Connective Tissue Disease Market in depth study and analysis published, 2018

Market Scenario

Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.

The specific cause of this disorder is unknown but the genetic patterns are considered to escalate the risk for developing connective tissue diseases. The connective tissue diseases arises due to changes in certain genes are often known as heritable disorders of connective tissue. Some of the common inherited disorders are Ehlers-Danlos syndrome (EDS), Epidermolysis bullosa (EB), Marfan Syndrome, and Osteogenesis imperfect. EDS is an amalgamation of more than 10 disorders, characterized by stretchy skin, over-flexible joints, and abnormal growth of scar tissue. Various autoimmune diseases are also associated with connective tissue disorders, which includes polymyositis and dermatomyositis, rheumatoid arthritis (RA), Sjögren's syndrome, and vasculitis. Mixed connective tissue disease (MCTD) is another rare autoimmune disease, consisting of characteristic features of several diseases such as lupus, polymyositis or dermatomyositis, scleroderma, and rheumatoid arthritis. According to the National Center for Advancing Translational Medicines, currently there is no cure available for this condition but certain medications such as corticosteroids, immunosuppresive drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs) help in the management of symptoms. It is also stated that MCTD is more frequent in females with a male to female ratio of 1:3, and the typical age of onset of MCTD is between 15-25 years.

Notably, the market is expected to expand in the near future due to the rising prevalence of various connective tissue disorders, high unmet needs of current treatment, and surge in the research and development expenditure.

Despite these drivers, there are some issues associated with connective tissue disease market. Lack of infrastructure in the middle and low income countries may hamper the growth of the market.

It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.

Intended Audience

Hospitals
Diagnostic clinics
Research and Development (R&D) Companies
Government Research Institute
Academic Institutes and Universities

Segmentation

The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.

On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others

On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.

Regional Analysis

The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.

Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.

Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.

The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities.

Key Players

Some of key the players in the market are Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, Pfizer, AutoImmune Inc., Johnson & Johnson, Amgen Inc., AstraZeneca, Eli Lilly and Company, Biogen, LUPIN, and others.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4977